Vivos Therapeutics (VVOS)
NASDAQ:VVOS
Want to see VVOS full AI Analyst Report?
Top Page
Vivos Therapeutics
(NASDAQ:VVOS)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.95
▼(-57.43% Downside)
Action:ReiteratedDate:04/18/26
The score is weighed down primarily by weak financial performance (ongoing large losses, persistent cash burn, and a materially weakened 2025 balance sheet with higher leverage). Technicals also remain bearish with the stock below key moving averages and negative MACD. The earnings call adds some offsetting upside from the pivot-driven growth narrative and stated path to cash-flow positivity, but near-term liquidity and execution risks remain significant.
Positive Factors
High, Stable Gross Margin
A sustained ~60% gross margin indicates durable unit economics that can support scalable service expansion and provider-affiliate rollouts. Stable product and service margins give management room to invest in provider networks while protecting contribution per patient as volumes scale.
Negative Factors
Weakened Balance Sheet & Higher Leverage
Negative shareholder equity and a sharp increase in debt materially weaken financial flexibility and raise refinancing and covenant risk. Increased leverage constrains strategic optionality, heightens dilution likelihood on future raises, and reduces the firm's ability to absorb execution delays.
Read all positive and negative factors
Positive Factors
Negative Factors
High, Stable Gross Margin
A sustained ~60% gross margin indicates durable unit economics that can support scalable service expansion and provider-affiliate rollouts. Stable product and service margins give management room to invest in provider networks while protecting contribution per patient as volumes scale.
Read all positive factors
Vivos Therapeutics (VVOS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$15.39M
Dividend YieldN/A
Average Volume (3M)421.86K
Price to Earnings (P/E)―
Beta (1Y)1.24
Revenue Growth18.76%
EPS Growth60.09%
CountryUS
Employees109
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-2.07
Shares Outstanding10,467,788
10 Day Avg. Volume324,525
30 Day Avg. Volume421,860
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)-14.00
Price to Sales (P/S)1.20
P/FCF Ratio-1.37
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue0.96
Enterprise Value/Gross Profit1.59
Enterprise Value/Ebitda-0.86
Forecast
1Y Price Target
$2.13Price Target Upside-4.28% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.28
Revenue Forecast (FY)$31.02M
Vivos Therapeutics Business Overview & Revenue Model
Company Description
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasiv...
How the Company Makes Money
null...
Vivos Therapeutics Earnings Call Summary
Earnings Call Date:Apr 15, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 18, 2026
Earnings Call Sentiment Neutral
The call presents a mixed but constructive picture: operationally the company demonstrated meaningful progress from its strategic pivot (16% revenue growth, diagnostic and treatment revenue ramp, in-network payer wins, and strong patient demand), and it is building a scalable affiliation model with attractive per-team economics. However, these achievements are offset by sizable near-term financial challenges — a large FY2025 net loss ($21.2M), sharply higher operating expenses, meaningful cash burn, a thin year-end cash balance ($2M), and increased liabilities including short-term debt due in 2026. Management has raised post-period capital and expects revenue and provider staffing to improve in 2026, but continued execution and additional financing will be required to fully realize the upside. Overall, positives and negatives are roughly balanced.Positive Updates
Full-Year Revenue and Gross Profit Growth
Revenue increased by $2.4 million or 16% year-over-year for FY2025. Gross profit rose to $10.5 million (a 17% increase) while gross margin remained steady at 60% year-over-year.
Negative Updates
Significant Increase in Operating Expenses and Large Net Loss
Operating expenses rose to $30.4 million for FY2025 from $20.2 million in FY2024 (an increase of $10.2 million). General and administrative expenses increased by $9.8 million to $27.7 million. Net loss widened to $21.2 million for the year, reflecting sizable ramp-up and integration costs (including roughly $1.6 million of one-time professional fees and ~$1.4 million of other one-time out-of-pocket costs).
Read all updates
Q4-2025 Updates
Positive
Negative
Full-Year Revenue and Gross Profit Growth
Revenue increased by $2.4 million or 16% year-over-year for FY2025. Gross profit rose to $10.5 million (a 17% increase) while gross margin remained steady at 60% year-over-year.
Read all positive updates
Company Guidance
The company guided that its pivot to a medical-provider model should drive stronger 2026 revenue and margins, noting full‑year 2025 results included a $2.4M (16%) revenue increase driven by ~ $6.0M in sleep testing services (up ~$4.8M) and ~$2.2M in treatment revenue from 2 SCN locations, while product revenue fell ~$1.4M and VIP enrollment and sponsorship revenues declined ~$2.0M and ~$0.7M respectively; Vivos sold 25,441 appliances/tooth positioners for ~$6.5M in 2025 (vs. 16,182 for ~$7.9M in 2024). Cost of sales rose ~$0.9M (15%) to $6.9M, gross profit was $10.5M (+17%) with gross margin steady at 60%, operating expenses were $30.4M (vs. $20.2M), net loss was $21.2M, cash used in ops ~$15.3M, liabilities ~$26.7M, and cash ~$2.0M as of 12/31/25; post‑year financings added $4.6M (Jan 2026) and $2.25M (Apr 2026). Management expects SO teams (currently ~1.5 deployed) to ramp in ~60 days (full collections ~6+ months), projects each SO team could generate >$500K/month with contribution margins >50% and current Nevada revenue/case just under $5,000, and reiterated a goal of achieving cash‑flow positive operations by year‑end 2026 (CFO noted a need to roughly double a ~$17M run‑rate by 2027 to reach net‑income positive).Vivos Therapeutics Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
18
Very Negative
Cash Flow
20
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 17.44M | 15.03M | 13.80M | 16.02M | 16.89M |
| Gross Profit | 10.54M | 9.02M | 8.27M | 10.02M | 12.60M |
| EBITDA | -18.59M | -10.55M | -16.68M | -24.36M | -19.54M |
| Net Income | -21.23M | -11.14M | -13.58M | -23.84M | -20.29M |
Balance Sheet | |||||
| Total Assets | 25.15M | 15.28M | 10.73M | 13.72M | 33.69M |
| Cash, Cash Equivalents and Short-Term Investments | 2.03M | 6.26M | 1.64M | 3.52M | 24.03M |
| Total Debt | 13.03M | 1.51M | 2.00M | 2.41M | 1.63M |
| Total Liabilities | 26.70M | 7.33M | 10.32M | 8.92M | 8.15M |
| Stockholders Equity | -1.49M | 7.95M | 411.00K | 4.80M | 25.54M |
Cash Flow | |||||
| Free Cash Flow | -15.26M | -13.26M | -12.75M | -20.51M | -18.13M |
| Operating Cash Flow | -15.26M | -12.69M | -11.95M | -19.59M | -15.73M |
| Investing Cash Flow | -7.53M | -568.00K | -853.00K | -924.00K | -2.61M |
| Financing Cash Flow | 18.56M | 17.88M | 10.92M | 0.00 | 24.17M |
Vivos Therapeutics Technical Analysis
Negative
2.22
Price Trends
1.36
Negative
1.69
Negative
2.79
Negative
Market Momentum
-0.05
Positive
36.31
Neutral
28.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VVOS, the sentiment is Negative. The current price of 2.22 is above the 20-day moving average (MA) of 1.21, above the 50-day MA of 1.36, and below the 200-day MA of 2.79, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 36.31 is Neutral, neither overbought nor oversold. The STOCH value of 28.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VVOS.
Vivos Therapeutics Risk Analysis
Vivos Therapeutics disclosed 85 risk factors in its most recent earnings report. Vivos Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
The failure to expand our market penetration with DME distribution agreements would adversely affect our revenue and results of operations. Q4, 2023
2.
We face risks from negative publicity from unregistered oral appliances which has and may continue to hurt our sales. Q4, 2023
Vivos Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $31.76M | -1.58 | -312.04% | ― | -70.54% | 70.03% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $55.35M | -0.55 | 129.49% | ― | -25.18% | -9.71% | |
44 Neutral | $15.39M | ― | -335.47% | ― | 18.76% | 60.09% | |
44 Neutral | $18.00M | -27.32 | -148.64% | ― | 4.58% | 55.26% | |
43 Neutral | $5.12M | -0.07 | -70.27% | ― | -87.84% | 29.16% |
* Healthcare Sector Average
VVOS
Vivos Therapeutics
0.97
-1.23
-55.73%
IRIX
Iridex
1.06
0.03
2.91%
CODX
Co-Diagnostics
1.56
-9.10
-85.36%
ADGM
Adagio Medical Holdings
1.55
0.35
29.17%
COCH
Envoy Medical
0.71
-0.60
-45.95%
NXL
Nexalin Technology, Inc.
0.46
-1.27
-73.30%
Vivos Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Vivos Therapeutics Completes Private Placement to Bolster Liquidity
Positive
Apr 3, 2026
On March 31, 2026, Vivos Therapeutics, Inc. completed a private placement with V-Co Investors 3 LLC, an affiliate of existing sponsor New Seneca Partners, selling common stock, a pre-funded warrant and Series A and B common stock purchase warrants...
Executive/Board Changes
Vivos Therapeutics Appoints Gregg Johnson to Board
Positive
Feb 6, 2026
Effective February 4, 2026, Vivos Therapeutics appointed Gregg C. E. Johnson as an independent director to its board of directors, also assigning him to the compensation committee and compensating him in line with its standard non-employee directo...
Business Operations and StrategyPrivate Placements and Financing
Vivos Therapeutics Completes Warrant Inducement Financing Transaction
Neutral
Jan 20, 2026
On January 15, 2026, Vivos Therapeutics entered into a warrant inducement agreement with an institutional holder under which the investor agreed to exercise in full previously issued warrants from January 2023, November 2023 and February 2024 at a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.